About Us
Nanophysics & Beyond
Curadigm
The Management
Our Commitments
Healthcare Professionals
Scientific Publications
Patients
Patient Engagement
Investors
Corporate Presentation
Financial Calendar
Regulated Information
SEC Filings
Annual General Meetings
Shareholder Corner
Press Releases
Congresses & Events
Nanotalks
NBTXR3 Development
R&D Day
Our Expert Videos
Nanoblog
From Curie to Nano
Contact & Newsletter
Medical Device Vigilance – Pharmacovigilance
Medical Information
Join Us
Nous vous informons que ce site est conforme à la législation française actuelle sur les dispositifs médicaux.
Continuer
Rester sur la page
Scientific Clinical | Nanobiotix provides update on the global development of its lead product NBTXR3
Financial | Nanobiotix successfully completes approximately eur 27.2 million placement of new shares
31 October 2017
Scientific Clinical | Nanobiotix presented new clinical and pre-clinical data confirming NBTXR3’s significant potential role in Immuno-Oncology at SITC Annual Meeting
13 November 2017
Scientific Clinical | Nanobiotix provides update on the global development of its lead product NBTXR3
Published by
adminvl
on
9 November 2017
No translations available for this page
